Metraipolis › archive › dc_8e654d8d0c19

Asciminib — Wikipedia (en)

Source: Wikipedia (en)
Original: https://en.wikipedia.org/wiki/Asciminib
License (as archived): CC-BY-SA-4.0
Archived: 2026-11-10T02:43:56.574Z
SHA-256 of the archived text: 4970c819f53b41318020b8384a335f51ded49cb9a49f5b1a9fd42e58091b6897
Stable URL of this page: https://metraipolis.com/documento/dc_8e654d8d0c19

How to cite

Asciminib — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Asciminib (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_8e654d8d0c19 (Metraipolis archive dc_8e654d8d0c19, sha256 4970c819f53b41318020b8384a335f51ded49cb9a49f5b1a9fd42e58091b6897)

BibTeX

@misc{dc8e654d8d0c19,
  title = {Asciminib — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Asciminib},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_8e654d8d0c19; sha256 4970c819f53b41318020b8384a335f51ded49cb9a49f5b1a9fd42e58091b6897},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Asciminib. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. In the pooled safety population in participants with newly diagnosed and previously treated Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, the most common adverse reactions include musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea. The most common laboratory abnormalities include decreased lymphocyte count, decreased leukocyte count, decreased platelet count, decreased neutrophil count, and decreased calcium corrected. Asciminib was approved for medical use in the United States in October 2021, and in the European Union in August 2022.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Asciminib» — https://en.wikipedia.org/wiki/Asciminib
Wikidata Q27074535: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q27074535
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Asciminib?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1340735742, consultata il 2026-11-10T02:38:18.777Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 84f132aa2cd1d58bfb8ccfbc046252508e376d60ca313a99f871cfaaaa2b40c5